CEO Carmine Stengone was paid $3,409,448 in fiscal year 2025, ↓ down 30.4% from fiscal year 2024 (SEC filing 0001628280-26-028881 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,409,448 ↓ Carmine Stengone total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CTNM's next annual pay disclosure, estimated May 1, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Carmine Stengone | $655,620 | $0 | $0 | $2,291,640 | $450,739 | $0 | $11,449 | $3,409,448 |
| President and Chief Executive Officer | ||||||||
| Timothy Watkins | 359,501 | 225,000 | 0 | 984,556 | 176,085 | 0 | 18,181 | 1,763,323 |
| Chief Medical Officer and Head of Development | ||||||||
| Peter Slover | 487,487 | 0 | 0 | 840,268 | 238,869 | 0 | 11,279 | 1,577,903 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Carmine Stengone | $3,409,448 | $4,900,039 | — | ↓ −1,490,591 |
| Timothy Watkins | 1,763,323 | — | — | — |
| Peter Slover | 1,577,903 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Contineum Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper CTNM reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses CTNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CTNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Carmine Stengone | CEO | $3,409,448 |
| Peter Slover | CFO | $1,577,903 |
| Timothy Watkins | Executive | $1,763,323 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Diego Miralles | Director | $254,156 |
| Evert Schimmelpennink | Chair of the Board | $120,035 |
| Lori M. Lyons-Williams | Independent Director | $96,535 |
| Olivia Ware | Independent Director | $94,035 |
| Sarah Boyce | Independent Director | $93,035 |
| Todd Brady | Independent Director | $102,535 |
| Troy Ignelzi | Independent Director | $100,035 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Peter Slover | Option | 58,334 | 15.76 | — |
| Peter Slover | Option | 23,450 | 10.81 | — |
| Carmine Stengone | Option | 300,000 | 9.79 | — |
| Carmine Stengone | Option | 78,164 | 10.81 | — |
| Carmine Stengone | Option | 166,250 | 15.76 | — |
| Peter Slover | Option | 110,000 | 9.79 | — |
| Timothy Watkins | Option | 122,778 | 4.5 | — |
The company's compensation program is designed to attract and retain talented executives by providing a competitive base salary and annual incentive bonus based on individual and corporate performance goals, including product development and clinical trial advancement. Long-term incentives are provided through stock options to align executive interests with stockholder value.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-26 | — | — | — | — | — |
| 2025 | 2025-06-26 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-26 | —a |
| 2025 | 2025-06-26 | —b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Diego MirallesNot independent | $31,889 | $0 | $197,267 | — | $25,000 | $254,156 |
| Evert SchimmelpenninkIndependent · Board Chair · Compensation | 75,000 | 0 | 45,035 | — | 0 | 120,035 |
| Todd BradyIndependent · Audit · Compensation (Chair) | 57,500 | 0 | 45,035 | — | 0 | 102,535 |
| Troy IgnelziIndependent · Audit (Chair) | 55,000 | 0 | 45,035 | — | 0 | 100,035 |
| Lori M. Lyons-WilliamsIndependent · Audit · Nominating and Corporate Governance | 51,500 | 0 | 45,035 | — | 0 | 96,535 |
| Olivia WareIndependent · Compensation · Nominating and Corporate Governance | 49,000 | 0 | 45,035 | — | 0 | 94,035 |
| Sarah BoyceIndependent · Nominating and Corporate Governance (Chair) | 48,000 | 0 | 45,035 | — | 0 | 93,035 |
| Carmine N. StengoneEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $367,889 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $25,000 |
| Total cost of the board | $392,889 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Contineum Therapeutics | 2025 | Carmine Stengone | $655,620 | $0 | $2,291,640 | $450,739 | $3,409,448 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Carmine Stengone | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |
| 2 | Section 01, Timothy Watkins | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 1,763,323. Filing ↗machine: span 282198–282207 |
| 3 | Section 01, Peter Slover | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Executive Compensation”. As printed: 1,577,903. Filing ↗machine: span 277701–277710 |
| 4 | Section 08, Diego Miralles | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 254,156. Filing ↗machine: span 377777–378008 |
| 5 | Section 08, Evert Schimmelpennink | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 120,035. Filing ↗machine: span 374698–374929 |
| 6 | Section 08, Todd Brady | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 102,535. Filing ↗machine: span 371797–372028 |
| 7 | Section 08, Troy Ignelzi | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 100,035. Filing ↗machine: span 373243–373474 |
| 8 | Section 08, Lori M. Lyons-Williams | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 96,535. Filing ↗machine: span 379233–379463 |
| 9 | Section 08, Olivia Ware | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 94,035. Filing ↗machine: span 376143–376373 |
| 10 | Section 08, Sarah Boyce | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 93,035. Filing ↗machine: span 370322–370584 |
| 11 | Section 08, Carmine N. Stengone | DEF 14A | 2026-04-30 | 0001628280-26-028881 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 06, 2026 vote | Form 8-K | 2026-06-26 | 0001628280-26-045804 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 13 | Section 06, 2025 vote | Form 8-K | 2025-06-26 | 0001437749-25-021343 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 09b board cost (computed) | Computed | — | — | Cash 367,889 + equity 0 + all other 25,000 = 392,889, summed across the director compensation table rows.machine: formula: Σ = 392,889 |
| 16 | Contineum Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001628280-26-028881 | CEO total compensation as printed in Contineum Therapeutics's own proxy. As printed: 3,409,448. Filing ↗machine: span 271162–271171 |